Successful treatment of psoriasis with secukinumab constructed a new homeostasis of gut microbiome

Abstract Background: Secukinumab (an interleukin (IL)-17 inhibitor) has been reported to be able to alter gut microbiome composition in psoriatic patients. However, it still remains unclear the gut microbiota alteration and related functional changes caused by successful secukinumab therapy in psoriatic patients. In this study, fecal samples from healthy people as comtrol (H; n=35), psoriatic patients without therapy (BT; n=32) and patients after 5-month successful secukinumab treatment (AT; n=11) were collected., Then gut microbiomes were investigated using next-generation sequencing targeting 16S ribosomal RNA. Results: Successful secukinumab therapy caused a significantly elevated microbiota richness and biodiversity, as well as an alteration in the gut microbiota composition than psoriasis without therapy and healthy control. The psoriatic patients after secukinumab successful therapy showed a microbiota profile characterized by increased proportions of the phylum Firmicute, families Comamonadaceae and Erwiniaceae, and a reduction in the phylum Bacteroidota, compared to the other two groups. Besides, we discovered that secukinumab treatment group exhibited more significant abundance in contains mobile elements phenotype, form biofilms phenotype, gram positive phenotype, and less abundance in gram negative phenotype and potentially pathogenic phenotype by BugBase. Functional analysis showed the different COG pathways and KEGG pathways such as downregulated cardiovascular diseases pathway and upregulated infectious diseases between secukinumab therapy group and the other two groups.Conclusions: Secukinumab therapy enhanced the diversity of gut microbiota and altered the composition of the gut microbiome, which actually may construct a more stable homeostasis of gut microbiome with less potentially pathogenicity.